# PureTech founded entity Akili receives approval to market EndeavorRx in Europe

- Link: https://www.directorstalkinterviews.com/puretech-founded-entity-akili-receives-approval-to-market-endeavorrx-in-europe/412835496
- Published: 2020-06-23T08:15:01+01:00
- Author: Amilia Stone

**PureTech Health plc** (LON:PRTC), a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly differentiated medicines for
devastating diseases, has noted that its Founded Entity, Akili, today announced 
that it has received a Conformité Européenne (CE) Mark for EndeavorRx (AKL-T01) 
as a prescription-only digital therapeutic software intended for the treatment of
attention and inhibitory control deficits in paediatric patients with Attention 
Deficit Hyperactivity Disorder (ADHD). While EndeavorRx is not yet available in 
Europe, the CE Mark enables Akili to market EndeavorRx in European Economic Area(
EEA) member countries. ADHD is one of the most common psychiatric disorders in childhood
and nearly five per cent of children in Europe are diagnosed with the disorder.

The CE Mark follows last week’s US Food and Drug Administration (FDA) decision, 
which made EndeavorRx the first FDA-cleared prescription treatment delivered through
a video game and the first game-based therapeutic to be granted marketing authorisation
by the FDA for any type of condition. With a near-term focus on launching the EndeavorRx
prescription treatment in the US, Akili is exploring expansion opportunities in 
Europe as part of its global strategy. In March 2019, Akili announced a strategic
partnership with Shionogi & Co., Ltd. to develop and commercialise EndeavorRx in
Japan and Taiwan.  

The full text of the announcement from Akili is as follows:

**Akili Announces CE Mark Approval of ****EndeavorRx^(TM) Digital Treatment for 
Children with ADHD**

_Approval enables the future marketing of EndeavorRx in __European Economic Area
member countries_

Delivered through a video game experience, EndeavorRx has been studied across five
clinical studies including a large, randomised controlled trial

Akili today announced that it has received Conformité Européenne (CE) Mark certification
for EndeavorRx (AKL-T01), as a prescription-only digital therapeutic software intended
for the treatment of attention and inhibitory control deficits in paediatric patients
with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is one of the most common
psychiatric disorders in childhood and nearly five per cent of children in Europe
are diagnosed with the disorder.

The CE Mark follows last week’s US Food and Drug Administration (FDA) decision, 
which made EndeavorRx the first FDA-cleared prescription treatment delivered through
a video game.

> “Following our recent FDA clearance, the CE Mark is another important milestone
> for Akili,” **said Anil Jina, MD, chief medical officer of Akili. **“This approval
> provides a path for the future expansion into Europe and will allow us to offer
> a new non-drug treatment option to families of children living with ADHD.”

The CE Mark confirms that EndeavorRx meets quality standards for design, manufacture
and final inspection. While EndeavorRx is not yet available in Europe, the certification
enables Akili to market EndeavorRx in European Economic Area (EEA) member countries.
With a near-term focus on launching the EndeavorRx prescription treatment in the
US, the company is exploring expansion opportunities in Europe as part of its global
strategy. In March 2019, Akili announced a strategic partnership with Shionogi &
Co., Ltd. to develop and commercialise EndeavorRx in Japan and Taiwan.

EndeavorRx is built on the Akili Selective Stimulus Management engine (SSME^(TM))
proprietary technology that presents specific sensory stimuli and simultaneous motor
challenges designed to target and activate the neural systems that play a key role
in attention function while using adaptive algorithms to personalise the treatment
experience for each individual patient.

**Clinical Evidence Supporting EndeavorRx**

EndeavorRx has been studied across five clinical studies in more than 600 children
diagnosed with ADHD, including a prospective, randomised, controlled study published
in _The Lancet Digital Health_ journal, which showed EndeavorRx improved objective
measures of attention in children with _ADHD._ After four weeks of EndeavorRx treatment,
one-third of children no longer had a measurable attention deficit on at least one
measure of objective attention.  Further, about half of parents saw a clinically
meaningful change in their child’s day-to-day impairments after one month of treatment
with EndeavorRx; this increased to 68% after a second month of treatment. Improvements
in ADHD impairments following a month of treatment with EndeavorRx were maintained
for up to a month. No serious adverse events have been associated with EndeavorRx
in any study to date. Some study participants (9.3%) experienced non-serious treatment-
related adverse events with EndeavorRx, including frustration, headache, dizziness,
emotional reaction, nausea or aggression.

**About Akili**

Akili is combining scientific and clinical rigour with the ingenuity of the tech
and entertainment industries to challenge the status quo of medicine. Akili has 
pioneered the development of video game-based digital medicine to improve cognitive
function. Akili’s flagship product, EndeavorRx, is a prescription digital treatment
to address inattention in children with attention deficit hyperactivity disorder(
ADHD). Akili’s patented technology serves as the foundation of its products and 
is designed to directly activate the networks in the brain responsible for cognitive
function. Driven by Akili’s belief that effective medicine can also be fun and engaging,
Akili’s treatments are delivered through captivating action video game experiences
that drive engagement and compliance. For more information, please visit AkiliInteractive.
com.

> **Daphne Zohar, founder and chief executive officer of PureTech Health said: **“
> Akili’s European marketing authorisation today is an important milestone for families
> in Europe looking to help their children with ADHD. This is on the heels of the
> exciting news of Akili’s FDA clearance last week and Gelesis’ receipt of a European
> CE Mark for Plenity® earlier this month. We are so proud that two products developed
> from our unique R&D engine have now received marketing authorisation in both the
> US and Europe.”

Share on: